Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency

Eitemau Tebyg

• Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency
  gan: Wasserman, Richard L., et al.
  Cyhoeddwyd: (2016)
• Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease
  gan: Skoda-Smith, Suzanne, et al.
  Cyhoeddwyd: (2010)
• Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: a Pooled Analysis of Six Hizentra® Studies
  gan: Mallick, Rajiv, et al.
  Cyhoeddwyd: (2018)
• Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases
  gan: Kobrynski, Lisa
  Cyhoeddwyd: (2012)
• Efficacy and Safety of Hizentra(®), a New 20% Immunoglobulin Preparation for Subcutaneous Administration, in Pediatric Patients with Primary Immunodeficiency
  gan: Borte, Michael, et al.
  Cyhoeddwyd: (2011)